We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Gamida Cell's StemEx® Registration Study Receives Special Protocol Assessment from the FDA

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gamida Cell's StemEx® Registration Study Receives Special Protocol Assessment from the FDA "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Gamida Cell Ltd. has announced that it has reached an agreement under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) on the design of the global, pivotal, historical controlled registration study of StemEx® for the treatment of hematological malignancies.

Gamida Cell is developing StemEx® in a Joint Venture with Teva Pharmaceutical Industries Ltd

In response to the SPA application, the FDA stated in an official reply letter that "...the design and planned analysis of your study sufficiently address the study’s objectives and that this study is adequately designed to provide the necessary data that, depending upon outcome, could support a license application submission."

"We have worked hard, together with the FDA, to sculpt the design and analysis of the study," said Gamida Cell CEO Dr. Yael Margolin.

"Conducting a pivotal study under an SPA is an important achievement. Among other advantages, it provides an agreed upon roadmap for the management and analysis of the study's data, and thus reduces some of the risks involved in seeing a product to market."

"Assuming that all of the study endpoints are met, we are confident that, together with Teva, we will be able to bring StemEx® to the market in 2009 as planned."